-transparent.png){kind=logo}
The capacity of the human placenta to degrade 125I-labelled arginine vasopressin (125I-AVP) was studied in vitro using a dual circuit perfused lobule preparation. Seven placentas were perfused with the perfusate on the maternal side of the lobule containing 125I-AVP at the upper limit of the physiological range. On average, over a 30-min period, 48% of the 125I-AVP appeared to have been metabolized. With one exception, a patient whose labour was augmented with intravenous oxytocin, no 125I-AVP apparently crossed the placental lobule to the fetal circulation. These data indicate that the human placenta has a considerable capacity to degrade AVP.
Related Publications
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
January 1984,
Developmental pharmacology and therapeutics,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
November 1988,
The Journal of urology,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
October 1981,
Ginekologia polska,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
November 1986,
Endocrine reviews,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
April 1991,
Biochemical Society transactions,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
November 1995,
Regulatory peptides,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
June 1987,
The Journal of urology,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
February 1987,
The Journal of clinical endocrinology and metabolism,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
August 1993,
Acta paediatrica Japonica : Overseas edition,
M J Landon, and
D K Copas, and
E A Shiells, and
J M Davison
January 1986,
Acta endocrinologica. Supplementum,
